The role of heat shock protein 90 inhibition as a novel means of modulating ischemia/reperfusion injury in the kidney

热休克蛋白 90 抑制作为调节肾脏缺血/再灌注损伤的新方法的作用

• 批准号: MR/L001233/1
• 负责人: Stephen O'Neill
• 金额: $ 17.92万
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FL001233%2F1
• 关键词: role; heat; shock; protein; 90

BACKGROUND The kidneys are a pair of organs in the abdomen that are essential to life. They function to excrete waste products, as well as maintaining salt water balance and blood pressure. Progressive and irreversible reduction in kidney function over time is termed chronic kidney disease (CKD).While conservative management of CKD is successful in the early stages of the disease, some patients will unfortunately progress to end-stage (or established) renal disease (ESRD), which is the most severe form of CKD and is defined as an irreversible decline in kidney function that is severe enough to be fatal in the absence of either dialysis or transplantation. Dialysis is a process that substitutes for the kidneys in the tasks of filtering blood and removing waste products while kidney transplantation is an operative procedure to transfer a healthy kidney from a donor to a recipient who has kidney failure. Collectively these two treatments are known as renal replacement therapy (RRT).In the UK the number of patients on RRT is rising rapidly and between 2000 and 2006 increased by 35%. By 2009 the rate of persons commencing RRT in the UK was 109 per million of the population. For many of these patients kidney transplantation is the treatment of choice as it not only offers freedom from daily or alternate day dialysis, but leads to increased survival, quality of life and is cheaper for the health service. However, kidney transplantation is a victim of its own success and currently the number of patients awaiting a kidney transplant far outweighs the availability of donor organs. This problem is compounded by the fact that due to the technical process of transplantation 10% of kidneys never work and 40% have delayed function. This leads to patients either dying or being forced back onto dialysis, which is devastating for those who have waited many years to receive their transplant in the first place. Even for patients whose transplanted kidneys recover from a delay in graft function there is an adverse impact on the long term outcome of their transplanted kidney.Our research group seeks to identify drugs that may reduce organ injury caused by the transplantation procedure. We have identified a promising candidate drug that reduces damage in both kidney cells and mouse kidneys in experiments simulating the injury sustained during transplantation. We wish to study this drug in human transplant patients, but prior to this wish to establish exactly how it works.METHODSThe research will be conducted in the University of Edinburgh by a medical doctor with a research background who is training to be a Transplant Surgeon. He will be supervised by a Professor in Transplant Surgery, a Professor in Renal Medicine and a Professor of Cell Biology. Work will begin in a mouse model, where protective drug treatment will precede the clamping of the blood supply to one kidney and the removal of the other kidney, after which the mouse will recover. This is analogous to the injury caused to the organ during the transplantation procedure. The kidneys and blood from these mice will be analysed using various investigative techniques to determine the mechanism by which the drug protects the kidney. Work will then be extended to kidney cells in the laboratory. The effect of the drug on cellular behaviour of white blood cells, immune cells and kidney cells will be examined as well as the interaction between these cells. We will also evaluate cellular pathways causing inflammation as it is likely that one or more of these pathways is blocked by this drug. Cells will also be subjected to stresses similar to that of an organ being transplanted and the effects of the drug on inflammation pathways measured.

背景肾脏是腹部的一对器官，对生命至关重要。它们的功能是排泄废物，以及维持盐水平衡和血压。慢性肾脏病（CKD）是指肾脏功能随时间而进行性和不可逆的下降。虽然CKD的保守治疗在疾病的早期阶段是成功的，但有些患者会不幸地进展到终末期。（或已确诊的）肾病（ESRD），这是CKD的最严重形式，被定义为肾功能的不可逆下降，严重到足以在没有治疗的情况下致命。透析或移植。透析是一种替代肾脏过滤血液和清除废物的过程，而肾移植是一种将健康肾脏从供体转移到肾衰竭受体的手术程序。这两种治疗方法统称为肾脏替代治疗（RRT）。在英国，接受RRT的患者数量迅速增加，2000年至2006年增加了35%。到2009年，联合王国开始RRT的人数为每百万人口109人。对于这些患者中的许多人来说，肾移植是治疗的选择，因为它不仅提供了每日或隔日透析的自由，而且提高了生存率和生活质量，而且医疗服务更便宜。然而，肾移植是其自身成功的受害者，目前等待肾移植的患者人数远远超过供体器官的可用性。由于移植的技术过程，10%的肾脏无法工作，40%的肾脏功能延迟，这一事实使这个问题更加复杂。这导致患者死亡或被迫重新接受透析，这对于那些等待多年才接受移植的人来说是毁灭性的。即使对于移植肾从移植功能延迟中恢复的患者，也会对移植肾的长期结果产生不利影响。我们的研究小组寻求确定可能减少移植手术引起的器官损伤的药物。我们已经确定了一种有前途的候选药物，可以在模拟移植过程中持续损伤的实验中减少肾细胞和小鼠肾脏的损伤。我们希望在人类移植患者中研究这种药物，但在此之前，希望确切地确定它是如何工作的。METHODSThe研究将在爱丁堡大学进行，由一名具有研究背景的医生进行，他正在接受移植外科医生的培训。他将由移植外科教授、肾脏医学教授和细胞生物学教授监督。工作将在小鼠模型中开始，其中保护性药物治疗将在阻断一个肾脏的血液供应和移除另一个肾脏之前进行，之后小鼠将恢复。这类似于在移植过程中对器官造成的损伤。将使用各种研究技术分析这些小鼠的肾脏和血液，以确定药物保护肾脏的机制。然后，工作将扩展到实验室中的肾细胞。将检查药物对白色血细胞、免疫细胞和肾细胞的细胞行为的影响以及这些细胞之间的相互作用。我们还将评估引起炎症的细胞通路，因为这些通路中的一个或多个可能被这种药物阻断。细胞也将受到类似于移植器官的压力，并测量药物对炎症途径的影响。

项目成果

Challenges in early clinical drug development for ischemia-reperfusion injury in kidney transplantation.

肾移植缺血再灌注损伤早期临床药物开发的挑战。

• DOI: 10.1517/17460441.2015.1044967
• 发表时间: 2015
• 期刊: Expert opinion on drug discovery
• 影响因子: 6.3
• 作者: O'Neill S

Faster may be better for anastomosis time, but does it really affect survival?

吻合时间越快可能越好，但这真的会影响生存吗？

• DOI: 10.1111/tri.12546
• 发表时间: 2015
• 期刊: official journal of the European Society for Organ Transplantation
• 作者: O'Neill S

Debate: should we use variable adjusted life displays (VLAD) to identify variations in performance in general surgery?

• DOI: 10.1186/s12893-015-0087-0
• 发表时间: 2015-08-28
• 期刊: BMC surgery
• 影响因子: 1.9
• 作者: O Neill S;Wigmore SJ;Harrison EM
• 通讯作者: Harrison EM